Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer

Liu,Pengfei; Sun,Manna; Jiang,Wenhua; Zhao,Jinkun; Liang,Chunyong; Zhang,Huilai

doi:10.3892/ol.2016.5180

Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer

Authors:
- Pengfei Liu
- Manna Sun
- Wenhua Jiang
- Jinkun Zhao
- Chunyong Liang
- Huilai Zhang
View Affiliations

Affiliations: Department of Lymphoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China, School of Material Science and Engineering, Hebei University of Technology, Tianjin 300322, P.R. China, Department of Radiotherapy, The Second Hospital of Tianjin Medical University, Tianjin 300211, P.R. China, Department of Radiology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China
Published online on: September 23, 2016 https://doi.org/10.3892/ol.2016.5180
Pages: 3882-3888
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to identify the differentially expressed genes (DEGs) regulated by microRNA (miRNA)-221 and miRNA-222 that are associated with the resistance of breast cancer to fulvestrant. The GSE19777 transcription profile was downloaded from the Gene Expression Omnibus database, and includes data from three samples of antisense miRNA-221-transfected fulvestrant‑resistant MCF7‑FR breast cancer cells, three samples of antisense miRNA‑222‑transfected fulvestrant‑resistant MCF7‑FR cells and three samples of control inhibitor (green fluorescent protein)‑treated fulvestrant‑resistant MCF7‑FR cells. The linear models for microarray data package in R/Bioconductor was employed to screen for DEGs in the miRNA‑transfected cells, and the pheatmap package in R was used to perform two‑way clustering. Pathway enrichment was conducted using the Gene Set Enrichment Analysis tool. Furthermore, a miRNA‑messenger (m) RNA regulatory network depicting interactions between miRNA‑targeted upregulated DEGs was constructed and visualized using Cytoscape. In total, 492 and 404 DEGs were identified for the antisense miRNA‑221‑transfected MCF7‑FR cells and the antisense miRNA‑222‑transfected MCF7‑FR cells, respectively. Genes of the pentose phosphate pathway (PPP) were significantly enriched in the antisense miRNA‑221‑transfected MCF7‑FR cells. In addition, components of the Wnt signaling pathway and cell adhesion molecules (CAMs) were significantly enriched in the antisense miRNA‑222‑transfected MCF7‑FR cells. In the miRNA‑mRNA regulatory network, miRNA‑222 was demonstrated to target protocadherin 10 (PCDH10). The results of the present study suggested that the PPP and Wnt signaling pathways, as well as CAMs and PCDH10, may be associated with the resistance of breast cancer to fulvestrant.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ariazi EA, Ariazi JL, Cordera F and Jordan VC: Estrogen receptors as therapeutic targets in breast cancer. Curr Top Med Chem. 6:181–202. 2006. View Article : Google Scholar : PubMed/NCBI
3	Howell A: Fulvestrant (‘Faslodex’): Current and future role in breast cancer management. Crit Rev Oncol Hematol. 57:265–273. 2006. View Article : Google Scholar : PubMed/NCBI
4	Baumgarten SC and Frasor J: Minireview: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol. 26:360–371. 2012. View Article : Google Scholar : PubMed/NCBI
5	Xin F, Li M, Balch C, Thomson M, Fan MY, Liu Y, Hammond SM, Kim S and Nephew KP: Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics. 25:430–434. 2009. View Article : Google Scholar : PubMed/NCBI
6	Rao X, Di Leva G, Li M, Fang F, Devlin C, Hartman-Frey C, Burow ME, Lvan M, Croce CM and Nephew KP: MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene. 30:1082–1097. 2011. View Article : Google Scholar : PubMed/NCBI
7	Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, et al: Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: Final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol. 18:64–69. 2007. View Article : Google Scholar : PubMed/NCBI
8	Tangkeangsirisin W and Serrero G: GP88 (Progranulin) confers fulvestrant (Faslodex, ICI 182,780) resistance to human breast cancer cells. Adv Breast Cancer Res. 3:68–78. 2014. View Article : Google Scholar
9	Kirkegaard T, Yde CW, Kveiborg M and Lykkesfeldt AE: The broad-spectrum metalloproteinase inhibitor BB-94 inhibits growth, HER3 and Erk activation in fulvestrant-resistant breast cancer cell lines. Int J Oncol. 45:393–400. 2014.PubMed/NCBI
10	Afsari B, Geman D and Fertig EJ: Learning dysregulated pathways in cancers from differential variability analysis. Cancer Inform. 13(Suppl 5): S61–S67. 2014.
11	Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, Tibshirani R, Botstein D and Altman RB: Missing value estimation methods for DNA microarrays. Bioinformatics. 17:520–525. 2001. View Article : Google Scholar : PubMed/NCBI
12	Székely GJ and Rizzo ML: Hierarchical clustering via joint between-within distances: Extending Ward's minimum variance method. J Classif. 22:151–183. 2005. View Article : Google Scholar
13	Deza E and Deza MM: Encyclopedia of distances. 3rd. Springer-Verlag; Berlin: 2009, View Article : Google Scholar
14	Shi J and Walker MG: Gene Set Enrichment Analysis (GSEA) for Interpreting Gene Expression Profiles. Curr Bioinform. 2:133–137. 2007. View Article : Google Scholar
15	Gotea V and Ovcharenko I: DiRE: Identifying distant regulatory elements of co-expressed genes. Nucleic Acids Res. 36:(Web Server Issue). W133–W139. 2008. View Article : Google Scholar : PubMed/NCBI
16	Smoot ME, Ono K, Ruscheinski J, Wang PL and Ldeker T: Cytoscape 2.8: New features for data integration and network visualization. Bioinformatics. 27:431–432. 2011. View Article : Google Scholar : PubMed/NCBI
17	Tian WN, Braunstein LD, Apse K, Pang J, Rose M, Tian X and Stanton RC: Importance of glucose-6-phosphate dehydrogenase activity in cell death. Am J Physiol. 276:C1121–C1131. 1999.PubMed/NCBI
18	Riganti C, Gazzano E, Polimeni M, Aldieri E and Ghigo D: The pentose phosphate pathway: An antioxidant defense and a crossroad in tumor cell fate. Free Radic Biol Med. 53:421–436. 2012. View Article : Google Scholar : PubMed/NCBI
19	Richardson AD, Yang C, Osterman A and Smith JW: Central carbon metabolism in the progression of mammary carcinoma. Breast Cancer Res Treat. 110:297–307. 2008. View Article : Google Scholar : PubMed/NCBI
20	Lu X, Bennet B, Mu E, Rabinowitz J and Kang Y: Metabolomic changes accompanying transformation and acquisition of metastatic potential in a syngeneic mouse mammary tumor model. J Biol Chem. 285:9317–9321. 2010. View Article : Google Scholar : PubMed/NCBI
21	Cai J, Guan H, Fang L, Yang Y, Zhu X, Yuan J, Wu J and Li M: MicroRNA-374a activates Wnt/β-catenin signaling to promote breast cancer metastasis. J Clin Invest. 123:566–579. 2013.PubMed/NCBI
22	Bilir B, Kucuk O and Moreno CS: Wnt signaling blockage inhibits cell proliferation and migration, and induces apoptosis in triple-negative breast cancer cells. J Transl Med. 11:2802013. View Article : Google Scholar : PubMed/NCBI
23	Li DM and Feng YM: Signaling mechanism of cell adhesion molecules in breast cancer metastasis: Potential therapeutic targets. Breast Cancer Res Treat. 128:7–21. 2011. View Article : Google Scholar : PubMed/NCBI
24	Saadatmand S, de Kruijf EM, Sajet A, Dekker-Ensink NG, van Nes JG, Putter H, Smit VT, van de Velde CJ, Liefers GJ and Kuppen JK: Expression of cell adhesion molecules and prognosis in breast cancer. Br J Surg. 100:252–260. 2013. View Article : Google Scholar : PubMed/NCBI
25	Pines J, Toldo L and Lafont F: Cell to cell contact and extracellular matrix. Curr Opin Cell Biol. 10:5611998. View Article : Google Scholar : PubMed/NCBI
26	Ying J, Li H, Seng TJ, Langford C, Srivastava G, Tsao SW, Putti T, Murray P, Chan AT and Tao Q: Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation. Oncogene. 25:1070–1080. 2006. View Article : Google Scholar : PubMed/NCBI